Catalyst
Slingshot members are tracking this event:
Sanofi Genzyme (SNY) Begins Phase 3 COMET Trial Evaluating Second-Generation Enzyme Replacement Therapy NeoGAA in Treatment of Pompe Disease
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| Sanofi Genzyme |
|
|
SNY |
|
|
|
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 04, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Comet, Second-generation Enzyme Replacement Therapy, Neogaa, Pompe Disease
